Liver cancer is the sixth most commonly diagnosed cancer worldwide and the third leading cause of cancer death globally. In the United States, approximately 41,000 new cases are diagnosed each year, and incidence has more than tripled since 1980. The liver's critical role in metabolism, detoxification, and protein synthesis makes treatment decisions uniquely complex, as both the cancer and the underlying liver function must be considered.

The two main types of primary liver cancer are hepatocellular carcinoma (HCC), which accounts for roughly 80% of cases, and intrahepatic cholangiocarcinoma (bile duct cancer), which accounts for 10–15%. Treatment strategies differ significantly between these types.

Key Fact: Unlike most cancers, liver cancer often develops within a diseased organ. Approximately 80–90% of HCC cases arise in patients with underlying chronic liver disease or cirrhosis, making it essential to treat both the cancer and the liver condition simultaneously.

Risk Factors

Hepatocellular Carcinoma Risk Factors

Chronic hepatitis B (HBV) — The leading cause of HCC worldwide, responsible for approximately 50% of cases globally. HBV can cause HCC even without cirrhosis through direct oncogenic mechanisms (HBV DNA integration into the host genome).
Chronic hepatitis C (HCV) — The leading cause of HCC in the United States and Europe. HCV-related HCC almost always develops in the context of cirrhosis. Direct-acting antiviral (DAA) therapy has dramatically reduced but not eliminated HCC risk in treated patients.
Cirrhosis from any cause — Alcoholic liver disease, nonalcoholic steatohepatitis (NASH/MAFLD), autoimmune hepatitis, and other causes of cirrhosis all increase HCC risk.
Nonalcoholic fatty liver disease (NAFLD) — The fastest-growing risk factor for HCC in Western countries, driven by the obesity epidemic. NAFLD-related HCC can occasionally develop without cirrhosis.
Aflatoxin exposure — Dietary contamination with aflatoxin B1 (produced by Aspergillus fungi on stored grains and nuts) is a significant risk factor in sub-Saharan Africa and Southeast Asia.
Alcohol use — Heavy alcohol consumption (>3 drinks daily) increases HCC risk, particularly when combined with viral hepatitis or obesity.
Hereditary conditions — Hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency.

Cholangiocarcinoma Risk Factors

Primary sclerosing cholangitis (PSC)
Liver fluke infection (Opisthorchis viverrini, Clonorchis sinensis) — endemic in Southeast Asia
Biliary duct cysts (Caroli disease, choledochal cysts)
Hepatolithiasis (intrahepatic bile duct stones)
Chronic hepatitis B and C
Cirrhosis

Screening and Surveillance

Patients with cirrhosis or chronic HBV infection should undergo HCC surveillance with abdominal ultrasound every 6 months, with or without serum alpha-fetoprotein (AFP) measurement. This strategy has been shown to detect HCC at earlier stages and improve overall survival.

Important: If you have been diagnosed with cirrhosis, chronic hepatitis B, or chronic hepatitis C (even if treated), ask your doctor about regular liver cancer screening. Early detection of HCC offers the best chance for curative treatment including surgery or transplant.

Diagnosis and Staging

HCC has a unique diagnostic feature: it can be diagnosed by imaging alone without biopsy in the right clinical context. The LI-RADS (Liver Imaging Reporting and Data System) classification guides radiologists in characterizing liver lesions on contrast-enhanced CT or MRI. A lesion showing arterial phase hyperenhancement with washout on portal venous or delayed phases in a patient with cirrhosis is diagnostic for HCC.

Child-Pugh Score

The Child-Pugh classification is essential for treatment planning in HCC, as it assesses the severity of underlying liver dysfunction:

Class	Score	Description	Treatment Implications
Child-Pugh A	5–6	Well-compensated cirrhosis	Eligible for surgery, ablation, TACE, systemic therapy
Child-Pugh B	7–9	Significant functional compromise	Limited surgical options; may be eligible for transplant, TACE, or select systemic therapies
Child-Pugh C	10–15	Decompensated cirrhosis	Only transplant offers potential cure; best supportive care if not transplant eligible

The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used staging framework for HCC, as it integrates tumor burden, liver function (Child-Pugh), and patient performance status to guide treatment allocation.

Surgical Treatment

Liver Resection (Hepatectomy)

Surgical resection is the treatment of choice for HCC in patients without cirrhosis or with well-compensated cirrhosis (Child-Pugh A) who have a single tumor without portal hypertension. Resection can remove up to 70–80% of the liver volume in patients with normal liver function, as the liver has remarkable regenerative capacity.

Five-year survival rates after resection for early-stage HCC range from 50% to 70%. However, intrahepatic recurrence is common, with rates of 60–70% at 5 years, necessitating long-term surveillance.

Liver Transplantation and Milan Criteria

Liver transplantation is the only treatment that addresses both the cancer and the underlying liver disease. The Milan criteria define eligibility for transplant:

Milan Criteria: A single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, with no macrovascular invasion and no extrahepatic spread. Patients meeting these criteria achieve 5-year post-transplant survival rates of approximately 70–80% with recurrence rates below 15%.

Several expanded criteria (University of California San Francisco criteria, up-to-seven criteria) have been proposed to extend transplant eligibility while maintaining acceptable outcomes. Successful downstaging of tumors beyond Milan criteria using locoregional therapies (ablation, TACE, or radiation) can also qualify patients for transplant at some centers.

Locoregional Therapies

Ablation

Thermal ablation is the preferred treatment for very early-stage HCC (single tumor ≤2–3 cm) and an alternative to resection for patients with up to 3 tumors ≤3 cm who are not surgical candidates:

Radiofrequency ablation (RFA) — The most established ablation technique. Uses electrical current to generate heat and destroy tumor tissue. Most effective for tumors ≤3 cm.
Microwave ablation (MWA) — Uses electromagnetic energy to create larger and more predictable ablation zones. Increasingly preferred over RFA for tumors >3 cm and those near large blood vessels.
Cryoablation — Uses extreme cold to destroy tumor cells. Less commonly used for liver tumors but may be preferred in specific anatomic locations.

Transarterial Chemoembolization (TACE)

TACE is the standard of care for intermediate-stage HCC (multinodular tumors without vascular invasion or extrahepatic spread, BCLC Stage B). The procedure involves injecting chemotherapy agents (typically doxorubicin or cisplatin) mixed with an embolic material (Lipiodol or drug-eluting beads) directly into the hepatic artery feeding the tumor, simultaneously delivering high local drug concentrations and cutting off the tumor's blood supply.

TACE has been shown to improve survival compared to best supportive care, with median survival of approximately 20–26 months for intermediate-stage disease.

Transarterial Radioembolization (TARE/Y90)

Radioembolization uses microspheres loaded with yttrium-90 (Y90), a beta-emitting radioisotope, delivered through the hepatic artery. It is used for both intermediate and advanced-stage HCC and has a more favorable side effect profile than TACE, particularly in patients with portal vein thrombosis where TACE may be contraindicated.

Systemic Therapy

First-Line Treatment

Atezolizumab plus bevacizumab (Tecentriq + Avastin) — The current preferred first-line regimen based on the IMbrave150 trial, which showed superior overall survival and progression-free survival compared to sorafenib. Median OS was 19.2 months versus 13.4 months with sorafenib.
Durvalumab plus tremelimumab (Imfinzi + Imjudo) — The HIMALAYA trial established the STRIDE regimen (single high-dose tremelimumab plus durvalumab) as another first-line option with improved OS versus sorafenib.
Sorafenib (Nexavar) — A multi-kinase inhibitor that was the first systemic therapy to demonstrate survival benefit in advanced HCC (SHARP trial, 2007). Now used when immunotherapy is contraindicated.
Lenvatinib (Lenvima) — A multi-kinase inhibitor shown to be non-inferior to sorafenib in the REFLECT trial. An alternative when immunotherapy is not appropriate.

Second-Line Treatment

Cabozantinib (Cabometyx) — Improved OS versus placebo after prior sorafenib (CELESTIAL trial).
Regorafenib (Stivarga) — Improved OS versus placebo in patients who tolerated and progressed on sorafenib (RESORCE trial).
Ramucirumab (Cyramza) — An anti-VEGFR2 antibody approved for patients with AFP ≥400 ng/mL after prior sorafenib (REACH-2 trial).

Cholangiocarcinoma Treatment

Intrahepatic cholangiocarcinoma (iCCA) is treated differently from HCC:

Surgery — Resection is the only curative option and requires negative margins. Five-year survival after R0 resection ranges from 25% to 40%.
Chemotherapy — Gemcitabine plus cisplatin (the ABC-02 regimen) is the standard first-line systemic therapy, with median OS of approximately 11.7 months.
Targeted therapy — IDH1-mutant iCCA can be treated with ivosidenib (Tibsovo). FGFR2 fusion-positive iCCA can be treated with pemigatinib (Pemazyre) or futibatinib (Lytgobi).
Immunotherapy — Durvalumab added to gemcitabine/cisplatin improved OS in the TOPAZ-1 trial and is now a standard first-line option.

Prognosis and Follow-Up

Overall prognosis for liver cancer depends heavily on stage at diagnosis and underlying liver function:

BCLC Stage	Treatment	Median Survival
Very Early (0)	Resection, ablation, or transplant	>5 years
Early (A)	Resection, ablation, or transplant	3–5 years
Intermediate (B)	TACE	~20–26 months
Advanced (C)	Systemic therapy	~12–19 months
Terminal (D)	Best supportive care	~3–4 months

Liver Cancer: Diagnosis, Treatment & Liver Transplant Guide